Please login to the form below

Not currently logged in
Email:
Password:

armodafinil

This page shows the latest armodafinil news and features for those working in and with pharma, biotech and healthcare.

Teva halts development of Nuvigil in bipolar disorder

Teva halts development of Nuvigil in bipolar disorder

The Israel-based pharma company said that Nuvigil (armodafinil) failed to demonstrate it was significantly more effective than placebo during a phase III trial investigating its use as an adjunct therapy ... While this study demonstrated a numerical

Latest news

  • Teva suffers setback as Nuvigil fails late-stage trial Teva suffers setback as Nuvigil fails late-stage trial

    Nuvigil (armodafinil) did not show a significant improvement over placebo when added on to therapy with mood stabilisers or atypical antipsychotics in the study, which involved patients with major depression associated

  • Teva sees Q2 profits leap as US business recovers

    Other strong performers were Parkinson's disease drug Azilect (rasagiline), up 36 per cent to $95m, while Cephalon products Treanda (bendamustine) for leukaemia and narcolepsy treatment Nuvigil  (armodafinil) added $139m and

  • Cephalon jet lag application rejected

    Cephalon has dropped its bid to get its sleep disorder drug Nuvigil (armodafinil) approved as a treatment for jet lag after the marketing application was rejected by the US Food and

  • State of mind

    Armodafinil (Nuvigil, Cephalon) is currently being investigated as a therapy for bipolar disorders. ... A phase II trial is currently underway to assess the efficacy of armodafinil in patients with bipolar depression.

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics